|
Safety and Tolerability Study of FPTI in Patients With Leukemia Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Safety and Tolerability Study of FPTI in Patients With Leukemia conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Safety and Tolerability Study of FPTI in Patients With Leukemia Clinical research trials and Safety and Tolerability Study of FPTI in Patients With Leukemia health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Safety and Tolerability Study of FPTI in Patients With Leukemia. Safety and Tolerability Study of FPTI in Patients With Leukemia Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Safety and Tolerability Study of FPTI in Patients With Leukemia clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Safety and Tolerability Study of FPTI in Patients With Leukemia condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety and Tolerability Study of FPTI in Patients With Leukemia  Safety and Tolerability Study of FPTI in Patients With Leukemia
Safety and Tolerability Study of FPTI in Patients With Leukemia
For Condition: Leukemia, Lymphocytic,Blast Crisis,Leukemia, Myeloid, Chronic,Leukemia,Myelodysplastic Syndromes
Status: No longer recruiting
Sponsor(s): Schering-Plough ,
Synopsis: The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, or Acute Lymphoblastic Leukemia.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: INCLUSION Criteria: - Pathologically documented chronic myelogenous leukemia in blast crisis, myelodysplasia, acute myelogenous leukemia, or acute lymphocytic leukemia. - Life expectancy of 12 weeks or greater. - ECOG Performance Status less than or equal to 2. - Meets protocol requirements for specified laboratory values. - No manifestations of a malabsorption syndrome. EXCLUSION Criteria: - Patients who have received more than three chemotherapy regimens for more than three recurrences of the disease. - Poor medical risks because of nonmalignant systemic disease as well as those with active uncontrolled conditions. - Patients who have received investigational therapy of any type within 30 days prior to administration.
Total Enrollment: 90
Location and Contact Information:
Glasgow Royal Infirmary
Glasgow, ,
United Kingdom
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois,
United States
University of Newcastle upon Tyne
Newcastle upon Tyne, ,
United Kingdom
C.H.U. de Bordeaux, Groupe Hospitalier Bordeaux Sud - Haut Leveque
Pessac, ,
France
Medicinsk-Haematologisk Afd. B
Aarhus C, ,
Denmark
Arizona Cancer Center
Tucson, Arizona,
United States
University of Minnesota
Minneapolis, Minnesota,
United States
Seattle Cancer Care Alliance
Seattle, Washington, 98109-1023
United States
C.H.R.U. de Tours, Hospital Bretonneau
Tours, ,
France
C.H.U. de Strabourg, Hopital Civil
Strasbourg, ,
France
Dana Farber Cancer Institute
Boston, Massachusetts,
United States
Cross Cancer Institute
Edmonton, Alberta,
Canada
Weill Cornell Medical College
New York City, New York,
United States
Dana Farber Cancer Institute
Boston, Massachusetts,
United States
Unitersita di Bologna
Bologna, ,
Italy
Oregon Health Sciences University
Portland, Oregon,
United States
University Hosipital
Uppsala, ,
Sweden
C.H.U. Hospital de la Miletrie
Poitiers, ,
France
MD Anderson Cancer Center Dept of Leukemia
Houston, Texas,
United States
C.H.U. Hopital de la Miletrie
Poitiers, , 86021
France
Princess Margaret Hospital
Toronto, ,
Canada
Hopital Haut Leveque
Pessac Cedex, , 33604
France
University of Texas
Houston, Texas,
United States
Additional Information:
Study ID Numbers: P00701;
Study Start Date: June 2001
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00034684
Other Leukemia, Lymphocytic Studies:
1. Randomized double cord blood transplant study
2. Phase I Study of Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
3. A exploratory, open-label study of the investigational product, AG-858, in patients who are cytogenetically positive after treatment with Gleevecâ„¢.
4. Safety and Tolerability Study of FPTI in Patients With Leukemia
5. Randomized Trial of High-Dose Gleevec Alone or in Combination with Peg-Alpha Interferon and GM-CSF in Early Phase CML
Related Studies:
Other Leukemia, Lymphocytic Clinical Trials
Other Clinical Trials
Other Pessac Cedex Clinical Trials
Safety and Tolerability Study of FPTI in Patients With Leukemia
|
|
|
|
|
|
|
|
